SCHEMBL3025673

SCHEMBL3025673

O=c1[nH]c(-n2cccn2)nc2cc(F)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 5/20 0.43
TNKS O95271 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
PARP2 Q9UGN5 1/20 0.41
MGLL Q99685 4/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2C8 P10632 1/20 0.40
CYP2C9 P11712 1/20 0.40
KCNH2 Q12809 1/20 0.40
MAPT P10636 2/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PARP14 Q460N5 2/20 0.39
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3030884 0.90 TUBB4A (0.48) EGLN1TNKSTNKS2PARP2MGLL
SCHEMBL3027553 0.84 TUBB4A (0.37) EGLN1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3025380 0.84 AURKA (0.38) EGLN1TNKSTNKS2MAPTNPSR1
SCHEMBL3030790 0.84 TUBB4A (0.47) EGLN1MAPTHTTTUBB4ATUBB
SCHEMBL3031131 0.84 PARP1 (0.41) EGLN1TNKSTNKS2MGLLMAPT
SCHEMBL3037229 0.82 EGLN1 (0.46) EGLN1TNKSTNKS2PARP2MGLL
SCHEMBL3030437 0.82 HTR3A (0.52) EGLN1TNKSTNKS2PARP2MGLL
SCHEMBL1192166 0.81 MAPK1 (0.43) EGLN1CYP1A2CYP2C8CYP2C9KCNH2
SCHEMBL3025751 0.79 KMT2A (0.44) EGLN1CYP2C9MAOB
SCHEMBL3025223 0.78 NPC1 (0.47) EGLN1TNKSTNKS2MGLLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937078-B2 Quinazolinones as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-01-20 US disclosed
US-20100204226-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204226-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 EGLN1 7/4885TNKS 984/4885TNKS2 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.